Tedatioxetine

Tedatioxetine

Clinical data
Other names	Lu AA24530; Lu-AA-24530
ATC code	none
Legal status
Legal status	Investigational
Identifiers
IUPAC name 4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine
CAS Number	508233-95-2 Y
PubChem CID	9878913
ChemSpider	8054590 Y
UNII	5H681S8O3S
KEGG	D10170 N
Chemical and physical data
Formula	C18H21NS
Molar mass	283.43 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C=C1)=CC=C1SC2=C(C3CCNCC3)C=CC=C2
InChI InChI=1S/C18H21NS/c1-14-6-8-16(9-7-14)20-18-5-3-2-4-17(18)15-10-12-19-13-11-15/h2-9,15,19H,10-13H2,1H3 Y Key:CVASBKDYSQKLSO-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Tedatioxetine (developmental code name Lu AA24530) is an experimental antidepressant that was discovered by scientists at Lundbeck; in 2007 Lundbeck and Takeda entered into a partnership that included tedatioxetine but was focused on another, more advanced Lundbeck drug candidate, vortioxetine.

Tedatioxetine is reported to act as a triple reuptake inhibitor (serotonin > norepinephrine > dopamine) and 5-HT_2A, 5-HT_2C, 5-HT₃, and α_1A-adrenergic receptor antagonist.

As of 2009, it was in phase II clinical trials for major depressive disorder, but there have been no updates since then, and as of August 2013 it was no longer displayed on Lundbeck's product pipeline.

On May 10, 2016, all work on tedatioxetine stopped.

A Chinese patent shows that there has been interest in this compound outside of Lundbeck.

See also

• MIN-117
• TGBA01AD
• Vilazodone
• Vortioxetine

External links

• Lu AA24530 shows positive results in major depressive disorder phase II study